Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2000
06/22/2000WO2000035485A1 Soluble compositions of triphenylethylene antiestrogens
06/22/2000WO2000035478A1 Treatment of papillomavirus infections
06/22/2000WO2000035469A2 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
06/22/2000WO2000035462A1 Novel therapeutic application of low molecular weight heparin
06/22/2000WO2000035461A1 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
06/22/2000WO2000035460A2 Pharmaceutical formulations
06/22/2000WO2000035458A1 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide
06/22/2000WO2000035457A1 Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
06/22/2000WO2000035456A1 Transdermal delivery system containing buprenorphine
06/22/2000WO2000035455A1 Heteroaryl-aryl ureas as igf-1 receptor antagonists
06/22/2000WO2000035452A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
06/22/2000WO2000035450A1 Controlled/modified release oral methylphenidate formulations
06/22/2000WO2000035448A1 New pharmaceutical formulation
06/22/2000WO2000035447A1 Use of riluzole for treating acoustic traumas
06/22/2000WO2000035446A1 Thrombopoietin mimetics
06/22/2000WO2000035445A1 Doramectin formulations
06/22/2000WO2000035444A1 USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE
06/22/2000WO2000035443A1 Method and composition for the maintenance and restitution of gut integrity
06/22/2000WO2000035442A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
06/22/2000WO2000035441A2 Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol
06/22/2000WO2000035440A1 N-formyl hydroxylamine derivatives as antibacterial agents
06/22/2000WO2000035439A1 The process for manufacturing formulation of topical beta blockers with improved efficacy
06/22/2000WO2000035438A1 Compositions for increasing carotenoid levels
06/22/2000WO2000035437A2 Improving mental performance by increasing brain insulin sensitivity
06/22/2000WO2000035436A2 Treatment of arthritis with mek inhibitors
06/22/2000WO2000035435A1 Use of a mek inhibitor for preventing transplant rejection
06/22/2000WO2000035434A2 Compositions and methods for the treatment of anorectal disorders
06/22/2000WO2000035433A2 Methods for the prevention and treatment of post-surgical complications
06/22/2000WO2000035432A2 Improved viscoelastic compositions and methods of use
06/22/2000WO2000035431A2 Treatment of erectile dysfunction in diabetes patients
06/22/2000WO2000035430A2 Homer a new target of treating psychiatric disorders
06/22/2000WO2000035429A1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
06/22/2000WO2000035428A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/22/2000WO2000035426A2 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
06/22/2000WO2000035425A1 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
06/22/2000WO2000035423A1 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
06/22/2000WO2000035422A2 Method of administering a compound to multi-drug resistant cells
06/22/2000WO2000035420A2 Stable surgical irrigating solutions
06/22/2000WO2000035417A1 Pharmaceutical preparation for inhalation of an opioid
06/22/2000WO2000035408A2 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
06/22/2000WO2000035303A1 Fibre blend for enteral composition
06/22/2000WO2000035280A1 Exo-r-mecamylamine formulation and use in treatment
06/22/2000WO2000035279A1 Exo-s-mecamylamine formulation and use in treatment
06/22/2000WO2000024388A3 Combination of 5-aminosalicylic acid and a budesonide, 6-methyl prednisolone or prednisolone for treating inflammatory disorders of the intestinal tract
06/22/2000WO2000016632A3 Environmentally benign crop protection agents
06/22/2000WO2000012709A3 Phelix: a testis-specific protein expressed in cancer
06/22/2000WO2000012504A3 Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
06/22/2000WO2000012048A3 Carbapenem antibacterial compositions and methods of treatment
06/22/2000WO2000012045A3 Method for treating neurodegenerative disorders
06/22/2000WO2000012018A9 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures
06/22/2000WO2000011033A3 Expression and export of angiostatin and endostatin as immunofusins
06/22/2000WO2000009695A3 Drug targets in candida albicans
06/22/2000WO2000008948A3 Carbohydrate mixture
06/22/2000WO2000008004A8 Particle-forming compositions containing fused pyrrolocarbazoles
06/22/2000WO2000007624A3 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
06/22/2000WO2000007584B1 Method of reducing retinal ganglion cell degeneration
06/22/2000WO2000007582A3 Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
06/22/2000WO2000006736A3 Nucleic acids and proteins from group b streptococcus
06/22/2000WO2000004954A3 Novel urokinase inhibitors
06/22/2000WO2000004870A3 Composition for enhancing epidermal lipid production
06/22/2000WO2000004034A3 Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages
06/22/2000WO2000002542A3 Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug
06/22/2000WO2000000158A9 Alkylamines and their precursors as specific modulators of human gamma-delta t cell function
06/22/2000WO1999066942A9 Compounds obtained from salvia species having antiviral activity
06/22/2000WO1999055316A3 Kinase obtained from leishmania
06/22/2000WO1999054707A3 Fetal testing for prediction of low birth weight
06/22/2000WO1999048488A3 Methods for decreasing beta amyloid protein
06/22/2000WO1999038504A8 Pharmaceutical uses of optically pure (-)-bupropion
06/22/2000CA2727746A1 Quinolone vitronectin receptor antagonist pharmaceuticals
06/22/2000CA2393442A1 Exo-r-mecamylamine formulation and use in treatment
06/22/2000CA2362423A1 47 human secreted proteins
06/22/2000CA2355890A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
06/22/2000CA2355864A1 Thrombopoietin mimetics
06/22/2000CA2355775A1 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
06/22/2000CA2355714A1 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents
06/22/2000CA2355645A1 Increasing brain glucose utilization
06/22/2000CA2355300A1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
06/22/2000CA2355299A1 Novel ligands of nuclear receptor
06/22/2000CA2355276A1 Synthetic nucleic acid particle
06/22/2000CA2355249A1 Protease inhibitors
06/22/2000CA2355234A1 Quinoline derivatives
06/22/2000CA2355211A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000CA2355202A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000CA2355201A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000CA2355161A1 Biphenyl and biphenyl-analogous compounds as integrin antagonists
06/22/2000CA2355066A1 Extending graft survival by heme oxygenase-i expression induced immunomodulation
06/22/2000CA2354875A1 Piperazine derivatives
06/22/2000CA2354873A1 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
06/22/2000CA2354765A1 The process for manufacturing formulation of topical beta blockers with improved efficacy
06/22/2000CA2354601A1 Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
06/22/2000CA2354591A1 4-aryloxindoles as inhibitors of jnk protein kinases
06/22/2000CA2354543A1 Compositions and methods for the treatment of anorectal disorders
06/22/2000CA2354510A1 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
06/22/2000CA2354456A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354451A1 Halovir, an antiviral marine natural product, and derivatives thereof
06/22/2000CA2354422A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354402A1 4,5-pyrazinoxindoles as protein kinase inhibitors
06/22/2000CA2354323A1 Homer a new target of treating psychiatric disorders
06/22/2000CA2354156A1 Compositions and methods for therapy and diagnosis of ovarian cancer
06/22/2000CA2354061A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
1 ... 6295 6296 6297 6298 6299 6300 6301 6302 6303 6304 6305 6306 6307 6308 6309 6310 6311 6312 6313 6314 6315 ... 7860